gamma secretase Inhibitors
1 drugsAbout gamma secretase
Gamma secretase is an intramembrane protease that cleaves single-pass transmembrane proteins within the lipid bilayer, influencing cellular signaling pathways.
Gamma secretase is a therapeutic target, but currently there is no genetic evidence data available linking it to specific diseases.
There is one FDA-approved drug, OGSIVEO (small molecule), targeting gamma secretase, developed by SPRINGWORKS for an 'Other' therapeutic area.
Top gamma secretase Drugs
SPRINGWORKS is the only company with an approved gamma secretase-targeting drug.
The lack of competitors suggests high entry barriers or perceived risk in this target class.
gamma secretase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets gamma secretase, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
gamma secretase Clinical Trials 21 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on gamma secretase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 3 | 1 | 8 | 75% |
| Phase 2 | 7 | 1 | 1 | 5 | 50% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
gamma secretase Drug Approval Timeline (2023 - 2023)
OGSIVEO was first approved in 2023 and is the most recent approval for this target.
Recent approval suggests renewed interest, but limited history indicates uncertain long-term potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on gamma secretase. A trial counts if an approved drug acting on gamma secretase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.